PIK3CA and inflammatory breast carcinoma: Importantly, the PIK3CA mutations in IBC were independently associated with negative prognosis, since the metastasis-free survival for the PIK3CA mutant type was 26 months and for the PIK3CA wild-type was 101 months: this association was true in TNBC and HR-/HER2+ subgroups, but not in the HR+/HER2- subgroup of IBC [154].